Researchers shed light on the "dark matter" of the gut, revealing a species of fungus that could potentially help counter ...

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

GSK will buy efimosfermin, a liver disease drug in late-stage trials, for up to $2 billion from U.S. biotechnology firm ...

GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening ...

A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...

New research reveals that semaglutide significantly improves liver health in MASH patients. A new study published in the New ...

Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has demonstrated sustained efficacy in a late-stage trial of patients with ...

Discover how metabolic dysfunction-associated steatohepatitis (MASH) damages your liver, its connection to common health ...

GSK acquires Boston Pharmaceuticals' efimosfermin for up to $2 billion, targeting liver diseases like MASH and ALD.

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver ...

A pioneering research study details how the hormone FGF21 (fibroblast growth factor 21) can reverse the effects of fatty liver disease in mice. The hormone works primarily by signaling the brain to ...